Business context and reporting period
This is AcelRx Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2015, filed March 7, 2016. The request identifies TALPHERA, INC.; that does not match the registrant named in the supplied filing. AcelRx was a clinical-stage specialty pharmaceutical company developing sublingual sufentanil therapies for acute pain. It had no revenue from product sales during the period.
Key programs: ARX-04, an investigational single-dose product for medically supervised settings, remained in Phase 3 development. Zalviso, a patient-administered hospital pain system, had European Commission approval for post-operative pain, while its U.S. NDA remained subject to an FDA Complete Response Letter and further study. ARX-03 development was contingent on external funding; the company had discontinued active development of ARX-02.
Financial performance and position
Amounts below are in millions of dollars except per-share data. The filing reports fiscal-year results and unaudited fourth-quarter figures; quarterly results are not necessarily indicative of future periods.
| Metric | FY 2015 | FY 2014 | Q4 2015 | Q4 2014 |
|---|---|---|---|---|
| Revenue | $19.3 | $5.2 | $1.7 | $0.2 |
| Operating expenses | $39.2 | $42.9 | $9.3 | $12.0 |
| Operating loss | $(20.0) | $(37.6) | Not clearly provided for quarter | Not clearly provided for quarter |
| Net loss | $(24.4) | $(33.4) | $(10.5) | $(13.8) |
| Basic loss per share | $(0.55) | $(0.77) | $(0.24) | $(0.32) |
| Cash, cash equivalents and short-term investments at year-end | $113.5 | $75.4 | — | |
| Working capital at year-end | $106.2 | $62.6 | — |
- 2015 revenue comprised $14.9 million from the Grünenthal collaboration and $4.4 million under the Department of Defense (DoD) contract. Revenue was not recurring product-sales revenue.
- Research and development expense was $22.5 million, down 8% year over year; general and administrative expense was $14.2 million, down 23%. The company recorded $0.8 million of restructuring costs.
- Net cash used in operating activities was $20.0 million, versus $34.5 million in 2014. Financing activities provided $59.6 million, principally from $61.2 million net proceeds from the royalty monetization.
- At December 31, 2015, Hercules debt principal was $20.9 million. The liability recorded for the PDL royalty sale was $63.6 million. The royalty transaction’s estimated effective annual interest rate was approximately 14%; $2.4 million of non-cash interest expense was recognized in 2015.
- The company reported no meaningful product-sales margin: it had no product sales, and Zalviso supplied to Grünenthal was priced near direct cost with minimal markup. The filing does not provide a comparable overall gross margin measure.
Material changes versus prior periods
- Annual revenue rose to $19.3 million from $5.2 million in 2014, mainly due to the new DoD contract and the Zalviso European approval milestone; it remained below 2013’s $29.5 million.
- Annual net loss narrowed to $24.4 million from $33.4 million. Operating loss also narrowed, reflecting lower operating expenses and higher collaboration and contract revenue. The year included a $2.4 million non-cash interest charge tied to the PDL transaction and a $0.8 million tax provision related to the transaction.
- The September 2015 PDL transaction generated $65.0 million gross proceeds ($61.2 million net) in exchange for most European Zalviso royalties and 80% of the first four commercial milestones, subject to a $195.0 million cap.
- In 2015, the company reduced headcount by 19 employees, approximately 36%, after the FDA required another Zalviso clinical study. It also extended Hercules’ interest-only period; scheduled debt maturity was in 2017.
Outlook, risks and unusual items
- Management expected existing capital resources to fund operations through at least the first half of 2017, while cautioning that additional FDA requirements, commercialization spending, or other changes could shorten that runway. It expected continued significant losses in 2016 and beyond.
- Conditional targets were to complete ARX-04 studies SAP302 and SAP303 by Q3 2016 and submit an NDA in Q4 2016. The FDA had agreed that approximately 323 Zalviso-study patients could contribute supporting safety data. The DoD contract provided up to $17.0 million for ARX-04 development; funding reimburses eligible costs and is subject to audit.
- For Zalviso, the company planned to initiate IAP312 in Q1 2016, enrolling approximately 315 post-operative patients to assess device performance, and aimed to resubmit the U.S. NDA by the end of 2016 if results supported it. Neither approval nor the planned timing was assured. Grünenthal expected a European launch in the first half of 2016.
- Principal risks include FDA approval and device-performance requirements, clinical trial timing and outcomes, continued access to capital, debt repayment, dependence on Grünenthal and a concentrated customer base, and reliance on single-source manufacturers. Sufentanil is a Schedule II controlled substance; competition, reimbursement and pricing pressure also pose risks.
- Unusual items include the royalty monetization accounted for as a liability rather than sale proceeds in earnings, fair-value changes in warrant liabilities affecting other income, and a $0.5 million impairment of leasehold improvements. The securities class action was dismissed with prejudice in January 2016. Auditors issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Confirm the registrant identity: the supplied filing is for AcelRx Pharmaceuticals, Inc., not TALPHERA, INC.
- Review cash burn and runway assumptions against the added ARX-04 and Zalviso study costs, future commercial preparations, and the DoD reimbursement terms.
- Track FDA feedback and actual results/timing for SAP302, SAP303, and IAP312, including whether the studies support the planned filings.
- Assess the economics of the PDL arrangement, including the $195.0 million cap, royalty allocation, estimated interest rate, and remaining milestone and royalty rights.
- Check Hercules’ repayment terms, collateral provisions, and maturity obligations, as well as manufacturing capacity and backup-supplier readiness.
- Verify Grünenthal’s launch progress, supply forecasts, and resulting sales, milestones, and royalty receipts; no commercial Zalviso sales revenue had been recorded for 2015.